AbbVie Inc. ABBV
- Market cap
- $467.4B
- P/E
- 74.7×
Follow ABBV
AbbVie Inc. (ABBV) Price to free cash flow
As of 25 September 2026, AbbVie Inc. (ABBV) trades at a price to free cash flow of 25.7×. Over the past ten years it has ranged from 7.3× (August 2019) to 36.7× (January 2015); the current reading is higher than 95% of that period. That is above the Drug Manufacturers General industry median of 17.7× and above the Healthcare sector median of 19.5×.
Price to free cash flow, daily
Annual
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 22.7× | 28.70% |
| FY2024 | 17.6× | 37.64% |
| FY2023 | 12.8× | 7.99% |
| FY2022 | 11.9× | 8.82% |
| FY2021 | 10.9× | 2.44% |
| FY2020 | 10.6× | 3.62% |
| FY2019 | 10.3× | (7.58%) |
| FY2018 | 11.1× | (33.30%) |
| FY2017 | 16.7× | 7.96% |
| FY2016 | 15.4× | 12.22% |
Quarterly
| Period | Price to free cash flow | Change |
|---|---|---|
| Jun 2026 | 24.4× | 26.88% |
| Mar 2026 | 19.3× | (15.08%) |
| Dec 2025 | 22.7× | 9.03% |
| Sep 2025 | 20.8× | 15.65% |
| 42 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| GILD Gilead Sciences, Inc. compare | 14.5× |
| PFE Pfizer Inc. compare | 16.0× |
| NVS Novartis AG compare | 18.3× |
| MRK Merck & Co., Inc. compare | 22.9× |
| AMGN Amgen Inc. compare | 23.0× |
| ABBV AbbVie Inc. | 25.7× |
| JNJ Johnson & Johnson compare | 28.7× |
| AZN AstraZeneca PLC compare | 41.2× |
| LLY Eli Lilly and Company compare | 51.8× |
| Drug Manufacturers General industry median | 17.7× |
| Healthcare sector median | 19.5× |
| Market median | 14.0× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on ABBV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement